The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma

Cancer

Volumn 82, Issue 10, 1998, Pages 1860-1866

  Stasi, Roberto ^a   Brunetti, Maurizio ^a   Parma, Albertina ^a   Di Giulio, Claudio ^a   Terzoli, Edmondo ^b   Pagano, Adalberto ^a  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

2 microglobulin; Interleukin 6 receptor; Multiple myeloma; Prognosis

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 6 RECEPTOR; NEOPTERIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; REGRESSION ANALYSIS; SOLUBILITY;

EID: 0032525085     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980515)82:10<1860::AID-CNCR7>3.0.CO;2-R     Document Type: Article

References (26)

1. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992;6:273-84.
2. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992;258:593-7.
3. Heaney MLK, Golde DW. Soluble hormone receptors. Blood 1993;82:1945-8.
4. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994;76:253-62.
5. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989;58:573-81.
6. Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, et al. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 1993;23:820-4.
7. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koshihara Y, et al. Soluble forms of interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993;82:1120-6.
8. Yasukawa K, Futatsugi K, Saito T, Yawata H, Narazaki M, Suzuki H, et al. Association of recombinant soluble IL-6-signal transducer. gp130, with a complex of IL-6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunol Lett 1992;31:123-30.
9. Klein B, Zhang X-G, Lu Z-Y, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
10. Klein B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin Hematol 1995;32:4-19.
11. Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Hoffbrand AV, Brown MC, Hirsch J, editors. Recent advances in hematology. Edinburgh: Churchill-Livingstone, 1977:243-61.
12. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting features, response to treatment, and survival. Cancer 1975:36:842-54.
13. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-202.
14. Ohtani K, Ninomiya H, Hasegawa Y, Kobayashi T, Kojima H, Nagasawa T, et al. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias. Br J Haematol 1995;91:116-20.
15. Kyrtsonis MC, Dedoussis G, Zervas C, Perifanis V, Baxevanis C, Stamatelou M, et al. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol 1996;93:398-400.
16. Papadaki H, Kyriakou D, Foudoulakis A, Markidou F, Alexandrakis M, Eliopoulos GD. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol 1997;97:191-5.
17. Pulkki K, Pelliniemi TT, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 1996;92:370-4.
18. Bataille R, Jourdan M, Zhang X-G, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-11.
19. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991;77:2794-5.
20. Brown R, Joshua D, Uhr E, Snowdon L, Gibson J. The use of a commercially available immunoassay to determine the level of interleukin-6 in the serum of patients with myeloma. Leuk Lymphoma 1991;5:151-5.
21. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991;78:1198-204.
22. Yasukawa K, Futatsugi K, Saito T, Yawata H, Narazaki M, Suzuki H, et al. Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunol Lett 1992;31:123-30.
23. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-7.
24. Pelliniemi T-T, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995;85:765-71.
25. Merlini G, Perfetti V, Gobbi PG, Quaglini S, Franciotta DM, Marinone G, et al. Acute phase proteins and prognosis in multiple myeloma. Br J Haematol 1993;83:595-601.
26. Durie BGM, Bataille R. Therapeutic implications of myeloma staging. Eur J Haematol 1989;43 (Suppl 51):111-6.